SCHEMBL4332717

SCHEMBL4332717

CSNC(=O)N/N=C/c1ccc(COc2ccc(Cl)c(Cl)c2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
HPGD P15428 6/20 0.49
NPSR1 Q6W5P4 4/20 0.49
KMT2A Q03164 9/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MEN1 O00255 5/20 0.47
POLB P06746 5/20 0.47
LMNA P02545 1/20 0.47
EYA2 O00167 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 5/20 0.42
DAO P14920 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPK1 P28482 1/20 0.41
BLM P54132 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334393 0.92 NPC1 (0.50) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4332722 0.81 MAPT (0.50) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL13612327 0.81 MAPT (0.50) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4336892 0.80 ALDH1A1 (0.61) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4336889 0.80 ALDH1A1 (0.61) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4453436 0.79 HPGD (0.70) MAPTHPGDNPSR1KMT2AMEN1
SCHEMBL4331625 0.74 MAPT (0.54) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4326578 0.74 MAPT (0.56) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4326572 0.74 MAPT (0.56) MAPTHPGDNPSR1KMT2ASMN1; SMN2
SCHEMBL4331633 0.74 MAPT (0.54) MAPTHPGDNPSR1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885HPGD 1646/4885NPSR1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.